💨 Abstract

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro (tirzepatide), in major emerging markets including India, Brazil, and Mexico in the second half of 2025. The drug, which has already been launched in the UK, Europe, and the US, is expected to benefit 900 million patients in these countries due to high obesity rates.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖